wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q50271158-4C53A629-52AD-44F5-A0C1-34AA138F7D3F
Q50271158-4C53A629-52AD-44F5-A0C1-34AA138F7D3F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50271158-4C53A629-52AD-44F5-A0C1-34AA138F7D3F
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
P2860
Q50271158-4C53A629-52AD-44F5-A0C1-34AA138F7D3F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50271158-4C53A629-52AD-44F5-A0C1-34AA138F7D3F
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
a2ec097de8792c4ce41c65ebcbffa13828fee4be
P2860
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205